![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/bone-therapeutics-final-asset-buried-after-failure-phase-2-fracture-study
https://www.fiercepharma.com/marketing/bone-therapeutics-breaks-old-name-rebrands-biosenic-biotech-names-change-rage-continues
https://www.globenewswire.com/news-release/2022/10/25/2540442/0/en/Bone-Therapeutics-to-start-a-new-Euronext-equity-story-with-a-change-of-name-to-BioSenic-following-the-acquisition-of-a-majority-participation-of-Medsenic-valued-at-EUR-40-million.html
https://www.globenewswire.com/news-release/2022/10/21/2538957/0/en/Bone-Therapeutics-provides-Third-Quarter-2022-Business-Update.html
https://www.globenewswire.com/news-release/2022/10/11/2531403/0/en/Bone-Therapeutics-SA-Transparency-notification-received-from-S-F-P-I-F-P-I-M.html
https://www.globenewswire.com/news-release/2022/10/07/2530066/0/en/Bone-Therapeutics-to-regain-worldwide-rights-to-ALLOB.html
https://www.globenewswire.com/news-release/2022/10/06/2529117/0/en/Bone-Therapeutics-to-host-Extraordinary-General-Meeting-on-24-October-2022.html
https://www.globenewswire.com/news-release/2022/08/31/2507254/0/en/Bone-Therapeutics-SA-Information-on-the-total-number-of-voting-rights-and-shares.html
https://www.globenewswire.com/news-release/2022/08/26/2505060/0/en/Bone-Therapeutics-to-host-Extraordinary-General-Meeting-on-26-September-2022.html
https://www.fiercebiotech.com/biotech/complex-fracturing-bone-brings-together-inflammatory-orthopedic-biotechs-reverse-merger